Hepion Pharmaceuticals Inc Stock price
Is Hepion Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Hepion Pharmaceuticals Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Hepion Pharmaceuticals Inc forecast:
Analyst Opinions
7 Analysts have issued a Hepion Pharmaceuticals Inc forecast:
Don't miss a Thing! We will send you all news about Hepion Pharmaceuticals Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
| Head office | United States |
| CEO | Dr. Lbiati |
| Employees | 22 |
| Founded | 2013 |
| Website | hepionpharma.com |


